Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Share Price Crosses Above Fifty Day Moving Average – Here’s What Happened

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) shares crossed above its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of $66.96 and traded as high as $68.71. Global X Genomics & Biotechnology ETF shares last traded at $67.90, with a volume of 30,031 shares traded.

Global X Genomics & Biotechnology ETF Price Performance

The stock’s fifty day simple moving average is $66.96 and its 200-day simple moving average is $53.96. The stock has a market cap of $107.28 million, a P/E ratio of -29.02 and a beta of 1.17.

Institutional Trading of Global X Genomics & Biotechnology ETF

Several hedge funds have recently made changes to their positions in the stock. Bank of America Corp DE boosted its position in Global X Genomics & Biotechnology ETF by 67.8% during the 1st quarter. Bank of America Corp DE now owns 119,795 shares of the company’s stock valued at $5,240,000 after purchasing an additional 48,394 shares during the period. Wealth Management Partners LLC grew its stake in Global X Genomics & Biotechnology ETF by 143.3% during the 3rd quarter. Wealth Management Partners LLC now owns 24,677 shares of the company’s stock worth $1,739,000 after buying an additional 14,533 shares during the last quarter. Polaris Financial Partners acquired a new stake in Global X Genomics & Biotechnology ETF in the third quarter worth $1,067,000. Farther Finance Advisors LLC acquired a new stake in Global X Genomics & Biotechnology ETF in the third quarter worth $257,000. Finally, Commonwealth Equity Services LLC acquired a new stake in Global X Genomics & Biotechnology ETF in the third quarter worth $220,000. Institutional investors own 56.95% of the company’s stock.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.